Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells.
Dendritic cell (DC)-based immunotherapy has been clinically evaluated, however, still requires modification to improve its outcomes. We previously demonstrated that DCs activated by replication competent recombinant Sendai virus (SeV) showed dramatic efficacy over that seen in use of current DC vaccine for immunotherapy against malignancies; however, application of replication-deficient vector is more relevant in clinical setting. We here show that F-gene-deleted non-transmissible Sendai virus (SeV/dF)-activated DCs (DCs/SeV/dF) has strong antitumor effects against murine SCCVII tumor, that was well-known as a less immunogenic cell line. SeV/dF shows high transfection efficiency to DCs and leads them to upregulate costimulatory molecules. Intratumoral injection of DCs/SeV/dF resulted in a marked and representative inhibition of the tumor, even when the tumors were well-vascularized. This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/dF-based cancer immunotherapy may, therefore, warrant further investigation.
Yoneyama
Yasuo
Y
Department of Gene Therapy, Chiba University, Chiba, Japan; Department of Frontier Surgery, Chiba University, Chiba, Japan.
Ueda
Yasuji
Y
Akutsu
Yasunori
Y
Matsunaga
Akinao
A
Shimada
Hideaki
H
Kato
Tomonori
T
Kubota-Akizawa
Megumi
M
Okano
Shinji
S
Shibata
Satoko
S
Sueishi
Katsuo
K
Hasegawa
Mamoru
M
Ochiai
Takenori
T
Yonemitsu
Yoshikazu
Y
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001854:Bone Marrow Cells / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology* / Q000821:virology*; D005260:Female; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D008809:Mice, Inbred C3H; D010253:Respirovirus Infections / Q000276:immunology* / Q000635:transmission; D029082:Sendai virus / Q000276:immunology*
D000276:Adjuvants, Immunologic